image
Healthcare - Drug Manufacturers - General - NASDAQ - UK
$ 76.715
0.663 %
$ 238 B
Market Cap
34.1
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Mar, 3, 2025.

The intrinsic value of one AZN stock under the worst case scenario is HIDDEN Compared to the current market price of 76.7 USD, AstraZeneca PLC is HIDDEN

This DCF valuation model was last updated on Mar, 3, 2025.

The intrinsic value of one AZN stock under the base case scenario is HIDDEN Compared to the current market price of 76.7 USD, AstraZeneca PLC is HIDDEN

This DCF valuation model was last updated on Mar, 3, 2025.

The intrinsic value of one AZN stock under the best case scenario is HIDDEN Compared to the current market price of 76.7 USD, AstraZeneca PLC is HIDDEN

2. FUNDAMENTAL ANALYSIS
FINANCIALS
54.1 B REVENUE
18.03%
10 B OPERATING INCOME
22.09%
8.69 B NET INCOME
25.97%
11.9 B OPERATING CASH FLOW
14.65%
-7.98 B INVESTING CASH FLOW
-96.36%
-4 B FINANCING CASH FLOW
39.15%
14.9 B REVENUE
9.78%
2.04 B OPERATING INCOME
-3.32%
1.67 B NET INCOME
-8.86%
2.91 B OPERATING CASH FLOW
-14.07%
-1.18 B INVESTING CASH FLOW
21.99%
-671 M FINANCING CASH FLOW
83.76%
Balance Sheet AstraZeneca PLC
image
Current Assets 25.8 B
Cash & Short-Term Investments 5.65 B
Receivables 0
Other Current Assets 20.2 B
Non-Current Assets 78.2 B
Long-Term Investments 1.73 B
PP&E 11.6 B
Other Non-Current Assets 64.8 B
Current Liabilities 27.9 B
Accounts Payable 22.5 B
Short-Term Debt 2.5 B
Other Current Liabilities 2.91 B
Non-Current Liabilities 35.3 B
Long-Term Debt 27.6 B
Other Non-Current Liabilities 7.68 B
EFFICIENCY
Earnings Waterfall AstraZeneca PLC
image
Revenue 54.1 B
Cost Of Revenue 10.2 B
Gross Profit 43.9 B
Operating Expenses 33.9 B
Operating Income 10 B
Other Expenses 1.31 B
Net Income 8.69 B
RATIOS
81.12% GROSS MARGIN
81.12%
18.50% OPERATING MARGIN
18.50%
13.01% NET MARGIN
13.01%
17.25% ROE
17.25%
6.76% ROA
6.76%
10.30% ROIC
10.30%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis AstraZeneca PLC
image
Net Income 8.69 B
Depreciation & Amortization 6.69 B
Capital Expenditures -4.59 B
Stock-Based Compensation 0
Change in Working Capital -893 M
Others -3.52 B
Free Cash Flow 7.28 B
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets AstraZeneca PLC
image
Wall Street analysts predict an average 1-year price target for AZN of $86 , with forecasts ranging from a low of $82 to a high of $89 .
AZN Lowest Price Target Wall Street Target
82 USD 6.89%
AZN Average Price Target Wall Street Target
86 USD 12.10%
AZN Highest Price Target Wall Street Target
89 USD 16.01%
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
1.03 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership AstraZeneca PLC
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
7. News
Levi & Korsinsky Notifies AstraZeneca PLC Investors of a Class Action Lawsuit and Upcoming Deadline - AZN NEW YORK, NY / ACCESS Newswire / February 21, 2025 / If you suffered a loss on your AstraZeneca PLC (NASDAQ:AZN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/astrazeneca-plc-lawsuit-submission-form?prid=131175&wire=1 or contact Joseph E. Levi, Esq. accessnewswire.com - 1 week ago
FINAL REMINDER AZN DEADLINE: Bronstein, Gewirtz & Grossman LLC Alerts AstraZeneca PLC Investors to Participate in the Class Action Lawsuit NEW YORK CITY, NY / ACCESS Newswire / February 21, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against AstraZeneca PLC ("AstraZeneca" or "the Company") (NASDAQ:AZN) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired AstraZeneca securities between February 23, 2022 and December 17, 2024, both dates inclusive (the "Class Period"). accessnewswire.com - 1 week ago
Lost Money on AstraZeneca PLC(AZN)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky NEW YORK , Feb. 21, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in AstraZeneca PLC ("AstraZeneca" or the "Company") (NASDAQ: AZN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of AstraZeneca investors who were adversely affected by alleged securities fraud between February 23, 2022 and December 17, 2024. prnewswire.com - 1 week ago
AZN Deadline: AZN Investors Have Opportunity to Lead AstraZeneca PLC Securities Fraud Lawsuit Filed by The Rosen Law Firm NEW YORK , Feb. 21, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of AstraZeneca PLC (NASDAQ: AZN) between February 23, 2022 and December 17, 2024, both dates inclusive (the "Class Period"), of the February 21, 2025 lead plaintiff deadline in the securities class action first filed by the Firm. So what: If you purchased AstraZeneca securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. prnewswire.com - 1 week ago
Levi & Korsinsky Notifies AstraZeneca PLC Investors of a Class Action Lawsuit and Upcoming Deadline - AZN NEW YORK, NY / ACCESS Newswire / February 20, 2025 / If you suffered a loss on your AstraZeneca PLC (NASDAQ:AZN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/astrazeneca-plc-lawsuit-submission-form?prid=131097&wire=1 or contact Joseph E. Levi, Esq. accessnewswire.com - 1 week ago
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 21, 2025 in AstraZeneca PLC Lawsuit - AZN NEW YORK, NY / ACCESS Newswire / February 20, 2025 / If you suffered a loss on your AstraZeneca PLC (NASDAQ:AZN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/astrazeneca-plc-lawsuit-submission-form?prid=131058&wire=1 or contact Joseph E. Levi, Esq. accessnewswire.com - 1 week ago
AstraZeneca PLC Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - AZN NEW YORK, NY / ACCESS Newswire / February 20, 2025 / If you suffered a loss on your AstraZeneca PLC (NASDAQ:AZN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/astrazeneca-plc-lawsuit-submission-form?prid=131030&wire=1 or contact Joseph E. Levi, Esq. accessnewswire.com - 1 week ago
Final Deadline for the AstraZeneca PLC Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - AZN LOS ANGELES , Feb. 20, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against AstraZeneca PLC ("AstraZeneca" or "the Company") (NASDAQ: AZN) for violations of the federal securities laws. Shareholders who purchased the Company's securities between February 23, 2022 and December 17, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before February 21, 2025. prnewswire.com - 1 week ago
AstraZeneca to Buy Fusion Pharmaceuticals for Up to $2.4B as Firm Expands Cancer Pipeline AstraZeneca Plc (AZN) on Tuesday said it will acquire biotech company Fusion Pharmaceuticals Inc. (FUSN) for up to $2.4 billion, expanding its pipeline of treatment for advanced prostate cancer. investopedia.com - 1 week ago
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of February 21, 2025 in AstraZeneca PLC Lawsuit – AZN NEW YORK, Feb. 20, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of AstraZeneca PLC (NASDAQ: AZN). globenewswire.com - 1 week ago
Amid Mounting Pressure In China, AstraZeneca Buys FibroGen's Chinese Unit For $160 Million FibroGen Inc. FGEN stock is trading higher on Thursday. The company announced the sale of its China subsidiary to AstraZeneca Plc AZN for approximately $160 million. benzinga.com - 1 week ago
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 21, 2025 in AstraZeneca PLC Lawsuit - AZN NEW YORK, NY / ACCESS Newswire / February 20, 2025 / If you suffered a loss on your AstraZeneca PLC (NASDAQ:AZN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/astrazeneca-plc-lawsuit-submission-form?prid=131005&wire=1 or contact Joseph E. Levi, Esq. accessnewswire.com - 1 week ago
8. Profile Summary

AstraZeneca PLC AZN

image
COUNTRY UK
INDUSTRY Drug Manufacturers - General
MARKET CAP $ 238 B
Dividend Yield 0.00%
Description AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Contact 1 Francis Crick Avenue, Cambridge, CB2 0AA https://www.astrazeneca.com
IPO Date May 12, 1993
Employees 94300
Officers Mr. Andrew P. Barnett Head of Investor Relations Ms. Ruth March Senior Vice President of Precision Medicine - R&D Oncology Mr. Joris Silon President of Bio Pharmaceutical Business Unit - US Ms. Pam P. Cheng EVice President of Global opt. & IT, Chief Sust. Officer and Member of External Sust.Adv. Board Ms. Iskra Reic Executive Vice President of International Prof. Maria Belvisi Senior Vice President & Head of Research & Early Dev., Respiratory, Inflammation & Autoimmunity, BioPharma R&D Dr. Aradhana Sarin M.D. Chief Financial Officer & Executive Director Dr. Ruud Dobber Ph.D. Executive Vice-President of BioPharmaceuticals Business Unit Gonzalo Vina Head of Global Media Relations Mr. Jeffrey Pott J.D. CHRO, Chief Compliance Officer, General Counsel & Member of External Sustainability Advisory Board